Achieving treatment goals in low-risk, asymptomatic patients.
Traditional risk factor assessments for coronary heart disease (CHD) often fail to take into account individual factors such as race and lipid profiles that may substantially elevate a patient's risk for CHD or a cardiovascular event. Although numerous treatment guidelines have been issued on metabolic syndrome, discrepancies among the guidelines can create confusion. Cardiac biomarkers and imaging methods have emerged to help detect and quantify subclinical atherosclerosis, but many of these are not proven as cost-effective for use in clinical practice or for routine screening. As the present case-based activity demonstrates, determining appropriate diagnostic and management strategies according to CHD risk is a process that challenges physicians to consider myriad individual patient variables.